A Belgian registry of interleukin-2 administration for treatment of metastatic renal cell cancer and confrontation with literature data

Acta Clinica Belgica

Volumn 62, Issue 4, 2007, Pages 223-229

  Bambust, I ^a   Van Aelst, F ^b   Joosens, E ^c   Schallier, D ^d   Rezaei Kalantari, H ^e   Paulus, R ^e   Renard, V ^a   Clausse, M ^f   Duck, L ^g   Luce, S ^h   Pierre, P ⁱ   Van Belle, S ^a   Rottey, Sylvie ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b Department of Neuroradiology   (Belgium)

^c Dienst radiologie ZNA Middelheim Antwerpen   (Belgium)

^d VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^e Department of Hematology Oncology   (Belgium)

^f Clinique St Luc Bouge   (Belgium)

^g Department of Oncology

^h ERASME HOSPITAL   (Belgium)

ⁱ Clinic Saint Joseph   (Belgium)

Author keywords

Cytokines; Metastatic renal cell cancer; Targeted drugs

Indexed keywords

ALPHA INTERFERON; FLUOROURACIL; INTERLEUKIN 2; SORAFENIB; SUNITINIB;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BELGIUM; CANCER PATIENT; CLINICAL ARTICLE; CORRELATION FUNCTION; DRUG TOLERANCE; FEMALE; HOPE; HOSPITAL; HUMAN; KIDNEY CARCINOMA; LITERATURE; MALE; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OBSERVATIONAL STUDY; REGISTER; THORAX DISEASE; UNSPECIFIED SIDE EFFECT;

EID: 34547801742     PISSN: 00015512     EISSN: None     Source Type: Journal    
DOI: 10.1179/acb.2007.036     Document Type: Article

References (32)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108.
2. Jacobsohn KM, Wood CG. Adjuvant therapy for renal cell carcinoma. Semin Oncol. 2006 Oct;33(5):576-82.
3. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med. 2005 Dec 8;353(23):2477-90.
4. Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev. 2005 Jan 25;(1):CD001425.
5. McDermott DF, Atkins MB. Interleukin-2 therapy of metastatic renal cell carcinoma - predictors of response. Semin Oncol. 2006 Oct;33(5):583-7.
6. George DJ, Kaelin WG Jr. The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer. N Engl J Med. 2003 Jul 31;349(5):419-21.
7. Choueiri TK, Bukowski RM, Rini BI. The current role of angiogenesis inhibitors in the treatment of renal cell carcinoma. Semin Oncol. 2006 Oct;33(5):596-606.
8. Ratain MJ, Eisen T, Stadler WM et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006 Jun 1;24(16):2505-12.
9. Escudier B, Eisen T, Stadler WM et al. TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007 Jan 11;356(2):125-34.
10. Motzer RJ, Michaelson MD, Redman BG et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006 Jan 1;24(1):16-24.
11. Motzer RJ, Rini BI, Bukowski RM et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006 Jun 7;295(21):2516-24.
12. Poster DS, Bruno S, Penta JS, Pinna K, Vilk P, Macdonald JS. Current status of chemotherapy, hormonal therapy, and immunotherapy in the treatment of renal cell carcinoma. Am J Clin Oncol. 1982 Feb;5(1):53-60.
13. Rosenberg SA, Lotze MT, Muul LM et al.A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987 Apr 9;316(15):889-97.
14. Fisher RI, Coltman CA Jr, Doroshow JH et al. Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial. Ann Intern Med. 1988 Apr;108(4):518-23.
15. Rosenberg SA, Lotze MT, Yang JC et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst. 1993 Apr 21;85(8):622-32.
16. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995 Mar;13(3):688-96.
17. Fyfe GA, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1996 Aug;14(8):2410-1.
18. Negrier S, Maral J, Drevon M, Vinke J, Escudier B, Philip T. Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe. Cancer J Sci Am. 2000 Feb;6 Suppl 1:S93-8.
19. Huland E, Heinzer H, Huland H, Yung R. Overview of interleukin-2 inhalation therapy. Cancer J Sci Am. 2000 Feb;6 Suppl 1:S104-12.
20. Yang JC, Sherry RM, Steinberg SM et al.Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol. 2003 Aug 15;21(16):3127-32.
21. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999 Aug;17(8):2530-40.
22. Symbas NP, Townsend MF, El-Galley R, Keane TE, Graham SD, Petros JA. Poor prognosis associated with thrombocytosis in patients with renal cell carcinoma. BJU Int. 2000 Aug;86(3):203-7.
23. Fahn HJ, Lee YH, Chen MT, Huang JK, Chen KK, Chang LS. The incidence and prognostic significance of humoral hypercalcemia in renal cell carcinoma J Urol. 1991 Feb;145(2):248-50.
24. Negrier S, Escudier B, Lasset C et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med. 1998 Apr 30;338(18):1272-8.
25. Figlin R, Gitlitz B, Franklin J et al. Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients. Cancer J Sci Am. 1997 Dec;3 Suppl 1:S92-7.
26. Atzpodien J, Kirchner H, Hanninen EL, Deckert M, Fenner M, Poliwoda H. Interleukin-2 in combination with interferon-alpha and 5-fluorouracil for metastatic renal cell cancer. Eur J Cancer. 1993;29A Suppl 5:S6-8.
27. Dutcher JP, Logan T, Gordon M et al. Phase ii trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study. Clin Cancer Res. 2000 Sep;6(9):3442-50.
28. Tourani JM, Pfister C, Berdah JF et al. Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized phase II study. Subcutaneous Administration Propeukin Program Cooperative Group. J Clin Oncol. 1998 Jul;16(7):2505-13.
29. Negrier S, Perol D, Ravaud A et al. Do cytokines improve survival in patients with metastatic renal cell cancer of intermediate prognosis? Results of the prospective randomized PERCY quattro trial. J Clin Oncol. 23: 2005 (abstr 4511).
30. Escudier B, Chevreau C, Lasset C et al. Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? Groupe Francais d'Immunotherape. J Clin Oncol. 1999 Jul;17(7):2039-43.
31. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001 Sep 22;358(9286):966-70.
32. Flanigan RC, Salmon SE, Blumenstein BA et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001 Dec 6;345(23):1655-9.